Related by context. All words. (Click for frequent words.) 84 Response Evaluation Criteria 82 Solid Tumors criteria 80 RECIST criteria 80 Solid Tumors 79 RECIST 76 Solid Tumors RECIST 75 Solid Tumours 73 CCyR 72 Index CDAI 70 bortezomib refractory 70 CR CRu 70 Pharmacokinetic parameters 70 EBMT criteria 70 Crohn Disease Activity 69 evaluable patients 68 response CCyR 68 Primary endpoints 68 DAS# CRP 68 ACTEMRA TM 67 evaluable 67 Psoriasis Area 67 Doxil ® 67 cytogenetic response 67 FDG-PET/CT 67 Tumor Response 67 FOLFOX6 67 FOLPI 67 immunohistochemical staining 67 plus dexamethasone 67 Follicular Lymphoma 67 underwent surgical resection 67 metastatic GIST 67 Virologic 67 Angiographic 66 remission CR 66 CIMZIA TM 66 Castration Resistant Prostate Cancer 66 complete cytogenetic 66 localized renal 66 ACR# responses 66 immunohistochemical 66 CIMZIA ™ 66 Secondary endpoints 66 viral kinetics 66 Score TOS 66 CDAI 66 neoadjuvant 66 specific antigen PSA 66 Rate ORR 66 Thrombolysis 66 cEVR 66 ACR# response 66 Severity MSCS score 66 achieved CCyR 66 relapsed MM 66 neoadjuvant therapy 66 biochemical relapse 66 Oral Fingolimod 65 CIMZIA TM certolizumab pegol 65 patients evaluable 65 Antitumor Activity 65 chemoradiation therapy 65 CRp 65 F FDG PET 65 #F FDG PET 65 mg BID dose 65 neoadjuvant chemotherapy 65 ZACTIMA 65 pCR 65 INCB# [003] 65 undetectable HBV DNA 65 mucosal healing 65 mg kg dose 65 metastatic malignant 65 recurrent glioblastoma multiforme 65 pT2 65 XIENCE V PROMUS Stent 65 Myocardial Infarction Study 65 Scale EDSS 65 Ejection Fraction 65 CR nPR 65 Kaplan Meier analysis 65 FOLFOX4 65 gemcitabine carboplatin 65 baseline LDH 65 Risk Stratification 65 MCyR 65 immunohistochemical analysis 65 MGd 65 confirmed CCyR 65 Acute Ischemic Stroke 65 Metastatic Renal Cell Carcinoma 65 renal tumors 65 adjuvant GIST 65 MAGE A3 ASCI 65 Severity Index PASI 65 EUS FNA 65 partial remissions 65 Flu Cy 64 ZOLINZA 64 ACR# ACR# 64 Diffuse Large B 64 HER2 expression 64 sunitinib Sutent 64 bronchial hyperresponsiveness 64 Treatment Outcome 64 haematologic 64 Free Survival PFS 64 Renal Cell Carcinoma RCC 64 papillary renal cell carcinoma 64 STRIDE PD 64 peg interferon 64 hemostatic efficacy 64 glomerular filtration 64 Renal Cell Carcinoma 64 clinicopathological features 64 resected pancreatic cancer 64 chemoradiotherapy 64 crizotinib PF # 64 sustained virological response 64 urothelial carcinoma 64 differentiated thyroid 64 Secondary endpoints include 64 8mg/kg 64 Pharmacodynamic 64 prospectively stratified 64 mg/m2 dose 64 Refractory Hodgkin Lymphoma 64 progression TTP 64 HES CEL 64 preoperative chemotherapy 64 debulking surgery 64 Folfox 64 secondary efficacy endpoint 64 fosbretabulin 64 calculated creatinine clearance 64 splenectomized patients 64 mcg QD 64 KRAS status 64 hA# 64 KRAS mutations occur 64 azacytidine 64 Hormone Refractory Prostate Cancer 64 histologically 64 Partial Response 64 cytologically confirmed 64 PSMA ADC 64 PEG IFN 64 TLUS 64 CTAP# Capsules 64 pathologic diagnosis 64 Placebo Controlled Trial 64 CTEPH 64 HCV RESPOND 2 64 undetectable HCV RNA 64 Brief Psychiatric 64 Clinical Outcome 64 leukocyte count 63 tumor histology 63 Histologic 63 Bezielle 63 lopinavir r arm 63 Carotid Revascularization Endarterectomy vs. 63 Cardiotoxicity 63 Advanced Renal Cell 63 stage IIIb IV 63 Severe Sepsis 63 EBUS FNA 63 Invasive Breast Cancer 63 Papillary 63 Golimumab 63 Cystatin C 63 Echocardiographic 63 Kaplan Meier estimates 63 resectable 63 Platinol ® 63 SVR# 63 mycophenolate mofetil 63 pain palliation 63 Severe Asthma 63 p# biomarker 63 dose cohort 63 TIMP 1 63 histopathologic 63 NMIBC 63 -#.# log# copies mL 63 surrogate endpoint 63 complete cytogenetic response 63 PSA nadir 63 follicular lymphomas 63 Relapsing Multiple Sclerosis 63 cisplatin gemcitabine 63 peripheral blood mononuclear 63 Secondary efficacy endpoints 63 prospectively defined 63 Prolongs Survival 63 Patients Receiving 63 colorectal liver metastases 63 immunosuppressive regimen 63 cinacalcet 63 median survivals 63 GLIADEL R Wafer 63 endoscopic remission 63 elevated ALT 63 Cytogenetic 63 Natalizumab 63 pegylated interferon alfa 2b 63 Montgomery Åsberg Depression 63 Neoadjuvant 63 Secondary endpoints included 63 breast carcinoma 63 urine cytology 63 histologically confirmed 63 relapsed MCL 63 chlorambucil 63 DAS# remission 63 gefitinib Iressa 63 stage IIIB 63 sipuleucel T 63 Neoadjuvant Chemotherapy 63 underwent resection 63 HBeAg positive patients 63 Decitabine 63 locoregional recurrence 63 Newly Diagnosed Multiple Myeloma 63 Autologous Stem Cell Transplantation 63 Survival Benefit 63 Skin sterol 63 intraobserver 63 HER2 positive metastatic breast 63 Progenitor Cells 63 ImmuKnow 63 Mean Symptom Complex 63 Antigen Specific 63 Pharmacokinetic 63 MabCampath 63 Amrubicin 63 HBeAg seroconversion 63 Tyrosine Kinase Inhibitor 63 antibody titer 63 Xelox 63 virologic responses 63 BENICAR HCT 63 histologic 63 thyroglobulin 63 abnormal p# biomarker 63 tipranavir ritonavir 63 Chronic Lymphocytic Leukemia 63 logistic regression analysis 63 FluCAM arm 63 Ranolazine 63 FDG PET 63 CT Angiography 62 PERSEUS 62 pegylated alpha interferon 62 CANCIDAS 62 bFGF 62 FDG PET imaging 62 DAS# [002] 62 recurrent NSCLC 62 Pemetrexed 62 plus prednisone 62 estimated glomerular filtration 62 NCCTG N# 62 ACR Pedi 62 icatibant 62 recurrent GBM 62 APPRAISE 62 standard chemotherapy regimen 62 multivariate Cox 62 ADCS CGIC 62 distant metastasis 62 vitro cytotoxicity 62 immunostaining 62 #F FDG PET CT 62 NSABP B 62 pancreatic adenocarcinoma 62 morphometric vertebral fractures 62 mCRC patients 62 pharmacodynamic effects 62 nonmetastatic 62 neoadjuvant treatment 62 HSCT 62 Adjuvant Chemotherapy 62 Kaplan Meier method 62 PSADT 62 ribavirin RBV 62 biochemical recurrence 62 HER2 overexpression 62 Histological 62 receiving highly emetogenic 62 AA Amyloidosis 62 renal cell carcinomas 62 radical nephrectomy 62 mRCC 62 cancer mCRC 62 preoperative PSA 62 Immunohistochemistry 62 K ras mutations 62 huN# DM1 62 Postoperative 62 serum prostate 62 parathyroidectomy 62 Squamous 62 Outpatient Setting 62 SABCS 62 galiximab 62 tumor lysis syndrome 62 ISTODAX ® 62 demonstrated antitumor activity 62 SUVmax 62 hematological parameters 62 HGPIN 62 evaluable subjects 62 Stent Restenosis 62 IV NSCLC 62 Montgomery Asberg Depression 62 Adenoma 62 postoperative chemotherapy 62 EURIDIS 62 cytogenic 62 pharmacodynamic profiles 62 Cardiopulmonary bypass 62 EGFR HER2 62 mapatumumab 62 invasive aspergillosis 62 Dose Escalation 62 adenotonsillectomy 62 Pharmacokinetics PK 62 epithelial tumors 62 Brain Metastases 62 Hurthle cell 62 PRECiSE 62 novel VDA molecule 62 locoregional disease 62 Myelodysplastic Syndromes 62 lactate dehydrogenase LDH 62 pharmacodynamic PD 62 teriflunomide 62 clinically meaningful improvement 62 certolizumab 62 mediastinal lymph nodes 62 Adenomas 62 lymphocytosis 62 Cystectomy 62 Lymphocytic 62 PROCHYMAL 62 Hamilton Anxiety Scale 62 univariate 62 mITT population 62 estimated GFR 62 ST Segment Elevation 62 transcranial Doppler ultrasound 62 metastatic neuroendocrine tumors 62 urine albumin 62 serum antibody 62 clinicopathological 62 metastatic renal cell carcinoma 62 pericardial effusion 62 Leukemias 62 ImmuKnow assay 62 PEGASYS ® 62 aminotransferase levels 62 Cardiorespiratory fitness 62 clinico pathological 62 multivariate regression analysis 62 Randomized Phase II 62 Cell Lymphoma 62 pharmacokinetic parameters 62 Prognostic Value 62 dacarbazine chemotherapy 62 alfa 2a 62 sUA 62 4mg/kg 62 concurrent chemoradiation 62 HCV SPRINT 62 NIHSS 62 Endometrial 62 prostate carcinoma 62 Sipuleucel T 62 serum urate 62 Subgroup analysis 62 corticosteroid dose 62 achieved sustained virological 62 epoetin alpha 62 KRAS wild 62 adalimumab Humira 61 Accelerated Partial Breast Irradiation 61 pharmacokinetic PK 61 % Confidence Interval 61 angiographic outcomes 61 DAS# scores 61 5 Fluorouracil 61 macroalbuminuria 61 VELCADE melphalan 61 metastatic pancreatic 61 pulmonary metastases 61 mucinous 61 BEXXAR Therapeutic Regimen 61 antibody MAb 61 modified RECIST criteria 61 binary restenosis 61 MAGE A3 61 achieved ACR# 61 estramustine 61 antiangiogenic therapy 61 recurrent metastatic 61 Retreatment 61 PEGylated anti 61 CIN2 + 61 pimecrolimus cream 61 Targeted Therapy 61 Capacity FVC 61 Cancer Incidence Mortality 61 mCi kg 61 DOXIL 61 elevated transaminases 61 serum clusterin levels 61 aminotransferase ALT 61 Aflibercept 61 medically inoperable 61 Randomized Study 61 Hematologic 61 sustained virologic response 61 Scale cognitive subscale 61 Omacetaxine 61 fine needle aspiration 61 Phase 2b Clinical Trial 61 See CLINICAL PHARMACOLOGY 61 Carotid Endarterectomy 61 pancreatic islet cell 61 Oral Mucositis 61 locoregional 61 BCIRG 61 Advanced Melanoma 61 hypofractionated 61 pharmacodynamic parameters 61 Events MACE 61 OvaRex MAb 61 Myelodysplastic Syndrome 61 oncologic outcomes 61 peginterferon alfa 2a #KD 61 ug kg 61 Group RTOG 61 Timed Walk 61 sarcomatoid 61 annualized relapse 61 bevacizumab Avastin ® 61 ARCOXIA 61 HIV RNA 61 Relapsed Refractory 61 Platinol ® cisplatin 61 semiquantitative 61 Non inferiority 61 Hematological 61 HAQ DI 61 intermittent dosing 61 μg kg 61 Expanded Disability Status 61 aspartate aminotransferase AST 61 PCWP 61 Antitumor 61 palliative radiotherapy 61 histological subtype 61 Colorectal Cancer Patients 61 Allogeneic 61 stage IIIA 61 cTnI 61 rFVIIa 61 Eculizumab 61 docetaxel Taxotere ® 61 refractory chronic lymphocytic 61 Engerix B 61 Pegasys ® 61 Hepatotoxicity 61 cytologic 61 QTcF 61 Rating Scale BPRS 61 Venous Thromboembolism 61 Patients Treated With 61 NATRECOR R 61 sirolimus stent 61 radiolabeled TM# 61 nodal metastasis 61 transvaginal sonography 61 Randomized Controlled Trials 61 Major Adverse Cardiac 61 malignant lymphoma 61 neurologic progression 61 microbiological eradication 61 TOP2A 61 urinary N telopeptide 61 prospective nonrandomized 61 Ocrelizumab 61 Multivariate logistic regression 61 evaluating REVLIMID 61 Guideline Update 61 EGFR TKI 61 pancreatic carcinoma 61 Stereotactic Body Radiation Therapy 61 myelodysplastic myeloproliferative diseases 61 Renal Function 61 Pralatrexate 61 CAMMS# 61 T1a 61 GAMMAGARD 61 DLQI 61 mg BID 61 surgically resected 61 prostate cancer PCa 61 colorectal carcinoma 61 GOUT 61 Anti Tumor Activity 61 Immunohistochemical analysis 61 Unified Parkinson Disease 61 MACCE 61 Adjuvant Treatment 61 MVax R 61 dasatinib Sprycel ® 61 adenoma recurrence 61 TO AVOID PREGNANCY WHILE 61 Adjuvant chemotherapy 61 mL/min/#.# m 2 61 antiretroviral naïve 61 Physical Function 61 nab paclitaxel 61 hormone receptor status 61 serum phosphorous 61 randomized multicenter trial 61 decitabine 61 Randomized Clinical Trial 61 mcg BID 61 iPTH 61 Preclinical Study 61 INC# 61 ductal carcinomas 61 Ki# 61 methotrexate monotherapy 61 abacavir lamivudine 61 myeloperoxidase 61 adjuvant radiation 61 curative resection 61 comparator arm 61 Ceplene/IL-2 61 Hycamtin ® 61 pertuzumab 61 Phase 2b Study 61 meta regression 61 fluvastatin 61 alteplase 61 KRAS mutations 61 tumor necrosis 61 NIH CPSI 61 intact parathyroid hormone 61 Score IPSS 61 pegylated liposomal doxorubicin 61 Vandetanib 61 EGFR expressing mCRC 61 detectable HCV RNA 61 adjuvant therapies 61 unresectable tumors 61 clinically localized prostate 61 Patency 61 advanced adenoma 61 genotypic resistance 61 clinicopathologic 61 nodular partial response 61 Tolerability 61 prospective multicenter study 61 hyperphenylalaninemia HPA due 61 HOMA IR 61 Relapsed Multiple Myeloma 61 Stage IIB 61 miRview ™ squamous 61 Interferon Beta 61 Adalimumab 61 -#.# log# 60 plasma pharmacokinetics 60 Gemcitabine 60 generalized edema 60 ritonavir boosted 60 preclinical efficacy 60 Degarelix 60 metastatic CRC 60 Median PFS 60 B Cell Lymphoma 60 Enzastaurin 60 Gleevec resistant 60 Functional Outcomes 60 myocardial viability 60 electrophysiologic 60 Carfilzomib 60 inhibitor RG# 60 gemcitabine cisplatin 60 Randomized Double blind 60 thalidomide Thalomid 60 complete Early Virological 60 Cutaneous T 60 serum HBV DNA 60 spirometric 60 EGFR mutation positive 60 hemagglutination inhibition 60 Combination REOLYSIN R 60 trastuzumab DM1 60 Hepatocellular Carcinoma HCC 60 TTF Therapy 60 Statistically Significant 60 seroprotection 60 differentiate squamous 60 Metastatic Prostate Cancer 60 immunohistochemistry IHC 60 Multivariate analysis 60 hepatectomy 60 riociguat 60 PEGylated Fab fragment 60 LEXIVA r 60 lung resection 60 histologic subtype 60 HBeAg negative patients 60 ongoing Phase 1b 60 β blockers 60 sunitinib Sutent ® 60 HERmark 60 Contrast Enhanced 60 Nymox NX 60 paclitaxel cisplatin 60 Kidney Disease Outcomes 60 thymoma 60 dose escalation phase 60 II Clinical Trial 60 IBDQ 60 RRM1 60 pretransplant 60 ertapenem 60 heavily pretreated patients 60 Azedra 60 definite stent thrombosis 60 visceral metastases 60 murine model 60 serum phosphate 60 Immunohistochemical 60 ALA PDT 60 gastric adenocarcinoma 60 hepatic metastases 60 DAVANAT 60 histopathological 60 pharmacokinetic equivalence 60 metastatic colorectal 60 Squamous Cell Carcinoma 60 Toxicities 60 ovarian carcinoma 60 systemic anaplastic large 60 peg IFN 60 Sentinel Lymph Node Biopsy 60 Induction Chemotherapy 60 Left Ventricular 60 fluoropyrimidine 60 fludarabine cyclophosphamide 60 leiomyomas 60 Trastuzumab 60 imatinib resistant 60 esophageal carcinoma 60 oral antidiabetic medication 60 multicenter randomized controlled 60 #mg BID [002] 60 coinfected patients 60 liposomal doxorubicin 60 melphalan prednisone 60 Subgroup analyzes 60 corticosteroids immunoglobulins 60 ribavirin therapy 60 severe neutropenia 60 5 FU leucovorin 60 Complete Remission 60 Metastatic Colorectal Cancer 60 Estrogen Receptor 60 Immunohistochemical staining 60 thyroid carcinoma 60 intracoronary 60 placebo dexamethasone 60 Clinical Practice Guideline 60 Demonstrates Sustained 60 Chronic Hepatitis C 60 Pegylated Liposomal Doxorubicin 60 ischemic cardiomyopathy 60 Radioimmunotherapy 60 clinically meaningful improvements 60 Relapsing Remitting Multiple Sclerosis 60 Microalbuminuria 60 postprocedure 60 myocardial necrosis 60 pT3 60 MR Angiography 60 FOLFOX 60 Complete Response CR 60 YMRS 60 familial amyloidotic polyneuropathy FAP 60 Pertuzumab 60 splenectomized 60 intravesical therapy 60 biliary tract cancer 60 basal bolus regimen 60 Intravesical 60 somatostatin analog 60 cytogenetic responses 60 Chronic Myelogenous Leukemia 60 virologic response 60 Elitek 60 octreotide LAR 60 median PFS 60 lymphadenectomy 60 Improves Outcomes 60 brivaracetam 60 Gliadel Wafer 60 allogeneic hematopoietic stem cell 60 Teriflunomide 60 Prospective Randomized 60 vismodegib 60 liver transplant recipients 60 ACR# [002] 60 TNM staging 60 p# biomarkers 60 myocardial revascularization 60 Improves Survival 60 Controlled Trial 60 Acute Myocardial Infarction 60 hemodynamic variables 60 sonographic findings 60 bronchoalveolar lavage fluid 60 SIR Spheres 60 chemoradiation 60 #mg BID [001] 60 adriamycin 60 miRview squamous 60 efaproxiral 60 PREZISTA r arm 60 R0 resection 60 BENICAR 60 intratumoral 60 Radiation Therapy Oncology 60 Randomized Phase 60 colorectal carcinomas 60 5-fluorouracil/leucovorin 60 sorafenib tablets 60 nomograms 60 serum HCV RNA 60 erlotinib Tarceva ® 60 Unstable Angina 60 prospective multicentre 60 DCE MRI 60 #mg QD [002] 60 liver resection 60 Kaplan Meier 60 Brentuximab Vedotin SGN 60 Localized Prostate Cancer 60 metastatic HRPC 60 oral FTY# 60 paclitaxel Taxol R 60 metachronous 60 follicular lymphoma FL 60 Prognostic 60 multigene expression test 60 Anticancer Drugs 60 acute myeloid 60 Surgical resection 60 chest radiographs 60 ara C 60 refractory NSCLC 60 NYHA functional class 60 Hemodialysis Patients 60 Virulizin ® 60 achieved sustained virologic 60 GSTP1 60 Septic Shock 60 hepatorenal syndrome 60 KRAS mutation 60 IFN α 60 Partial Responses 60 Phase Ib Clinical Trial 60 ixabepilone 60 IFN alfa 60 CLL SLL 60 adjuvant cisplatin 60 ACUITY trial 60 Visual Analog Scale 60 oral allopurinol 60 dimensional echocardiography 60 multivariate analyzes 60 Median progression 60 axitinib 60 PEG SN# 60 plus methotrexate 60 q#h 60 oxycodone CR 60 demonstrated clinically meaningful 60 IU ml 60 Atopic Dermatitis 60 hematopoietic cancers 60 alanine aminotransferase ALT 60 oral Hycamtin 60 TRAIL R1 60 Prospective Randomized Trial 60 Mouse Model 60 APOPTONE 60 pelvic lymphadenectomy 60 composite endpoint 60 EORTC 60 steroid dexamethasone 60 Sentinel Lymph Node 60 Bosutinib 60 Afatinib 60 fallopian tube cancers 60 lenalidomide Revlimid R 60 surgically resectable 60 Randomized trials 60 Gastric Cancer 60 complete remissions 60 Y BOCS 60 Prostate AdenoCarcinoma Treatment 60 rosuvastatin #mg 60 Newly Diagnosed Patients 60 immunoblotting 60 Tanespimycin 60 Traficet EN 60 dosage regimens 60 ULORIC 60 percutaneous biopsy 60 ADAS Cog 60 bronchoalveolar lavage 60 TRUS 60 Radiofrequency Ablation 60 EXPAREL ™ 60 Rating Scale MADRS 60 adenomatous 60 graft dysfunction 60 prognostic significance 60 liver histology 60 PASI scores 60 Prognostic Index 60 ELOXATIN 60 transrectal ultrasound guided 60 International Prostate Symptom 60 carcinoid 60 pharmacokinetic PK profile 60 docetaxel chemotherapy 60 squamous histology 60 T#I [002] 60 mg ustekinumab 60 Taxotere ® 60 RT qPCR 60 Metastatic Melanoma 60 Randomized Evaluation 60 perioperatively 60 Pharmacodynamics 60 intima media thickness 60 fluorodeoxyglucose positron emission tomography 60 Zevalin R Ibritumomab 60 everolimus eluting stents 60 oral ridaforolimus 60 Sustained virologic response 60 mm Stent 60 BRIM3 60 peginterferon alfa 2a 60 tumor progression TTP 60 sorafenib Nexavar 60 albumin excretion rate 59 cervical carcinoma 59 recurrent malignant glioma 59 RTOG 59 #mg dose [002] 59 quantitative coronary angiography 59 multiple myeloma MM 59 rituximab refractory 59 liposome injection 59 non squamous 59 treatment naive genotype 59 Zarnestra 59 EOquin TM 59 pituitary adenomas 59 International Prognostic Scoring 59 Bevacizumab 59 log# reduction 59 Breast Carcinoma 59 Common Toxicity Criteria 59 tipranavir r 59 BRIM2 59 HCV Genotype 59 Myeloproliferative Neoplasms 59 FDG uptake 59 FOLFIRI 59 plasma renin activity 59 JAK Inhibitor 59 Pooled Analysis 59 prostate cancer CaP 59 APTIVUS r 59 Health Assessment Questionnaire 59 malignant pleural mesothelioma 59 dose melphalan 59 CLARITY study 59 nausea photophobia 59 hypereosinophilic syndrome 59 Functional Assessment 59 Rheumatoid Arthritis Patients 59 antitumor effect 59 mesalamine granules 59 moderate renal impairment 59 Tiotropium 59 NSCLC tumors 59 RECORD1 59 angiographically 59 intravesical 59 mCi 59 Allovectin 7 ® 59 Disease Activity 59 PROactive study 59 System IPSS 59 PROLARIS 59 SYNTAX trial 59 malignant lesions 59 cytoreductive surgery 59 MTT assay 59 Fludara 59 Naive Patients 59 vincristine doxorubicin 59 LUX Lung 59 Idiopathic Pulmonary Fibrosis 59 Scale EDSS score 59 posttreatment 59 histologic subtypes 59 Renal Cancer 59 Pathologic 59 intradermal injections 59 seropositivity 59 activated partial thromboplastin 59 Gastrointestinal Stromal Tumors 59 phase IIIb 59 hematologic parameters 59 Adjuvant Therapy 59 Remission Maintenance 59 lymphoid malignancies 59 Temsirolimus 59 histopathologic examination 59 Non Responders 59 enzyme immunoassay EIA 59 desvenlafaxine succinate 59 Fluorouracil 59 Solid Tumor 59 Heterozygous Familial Hypercholesterolemia 59 transthoracic 59 Hypercholesterolemia 59 localized prostate 59 previously untreated follicular 59 IPSS 59 papillary thyroid carcinoma 59 xenograft models 59 relapsed refractory multiple myeloma 59 glomerular filtration rate 59 Factor Receptor 59 SLNB 59 randomized controlled trials RCTs 59 drug eluting stent implantation 59 achieved statistical significance 59 nondiabetic patients 59 Inflammatory Pain 59 q8h 59 NLX P# 59 metastatic gastric 59 pretreatment serum 59 evaluating tivozanib 59 Predict Response 59 Erlotinib 59 bronchoalveolar lavage BAL 59 radical prostatectomy RP 59 Logistic regression 59 logistic regression analyzes 59 % CI #.#-#.# [005] 59 thromboembolic complications 59 monoclonal antibody conjugated 59 symptomatic VTE 59 HuMax EGFr 59 unresectable 59 HORIZONS AMI trial 59 postoperative complication 59 Poster Discussion 59 platinum refractory 59 Neuropsychiatric Inventory NPI 59 posaconazole 59 R# #mg BID 59 trials RCTs 59 intravascular hemolysis 59 #mg/m# [002] 59 Achieves Primary Endpoint 59 BEACOPP 59 GW# [003] 59 Meta Analysis 59 Investigational Compound 59 Histopathologic 59 Well Tolerated 59 Dasatinib